In addition to the identification of TOP2A as one of the molecular targets of bDMC, our data highlight that NF-Y regulation can be an interesting approach in anti-cancer therapy, taking into consideration that (i) NF-Y is one of the transcription factors orchestrating oncogenic transcriptional changes,58, 59 and (ii) clinical studies correlated upregulated expression of NF-Y target genes to poor clinical prognosis in multiple types of cancer.60 Here, TOP2A is linked to cancer.